| [1] |
Alexandrova E, Smal M, Di Rosa D, et al. BRPF1 inhibition reduces migration and invasion of metastatic ovarian cancer cells, representing a potential therapeutic target[J]. Sci Rep, 2025, 15(1): 7602. DOI: 10.1038/s41598-025-92438-2.
|
| [2] |
Sharma J, Deo SVS, Kumar S, et al. Malignant chest wall tumors: complex defects and their management—a review of 181 cases[J]. Ann Surg Oncol, 2024, 31(6): 3675-3683. DOI: 10.1245/s10434-023-14765-w.
|
| [3] |
Thomakos N, Diakosavvas M, Machairiotis N, et al. Rare distant metastatic disease of ovarian and peritoneal carcinomatosis: a review of the literature[J]. Cancers(Basel), 2019, 11(8): 1044. DOI: 10.3390/cancers11081044.
|
| [4] |
Rakina M, Kazakova A, Villert A, et al. Spheroid formation and peritoneal metastasis in ovarian cancer: the role of stromal and immune components[J]. Int J Mol Sci, 2022, 23(11): 6215. DOI: 10.3390/ijms23116215.
|
| [5] |
Shen G, Kuang A. Recurrent ovarian cancer presenting as a solitary chest wall metastasis revealed by FDG PET/CT[J]. Clin Nucl Med, 2022, 47(4): 365-366. DOI: 10.1097/RLU.0000000000003958.
pmid: 35143461
|
| [6] |
Jackson GA, Adamson DC. Similarities in mechanisms of ovarian cancer metastasis and brain glioblastoma multiforme invasion suggest common therapeutic targets[J]. Cells, 2025, 14(3): 171. DOI: 10.3390/cells14030171.
|
| [7] |
Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia[J]. Carcinogenesis, 2021, 42(3): 327-343. DOI: 10.1093/carcin/bgab010.
pmid: 33608706
|
| [8] |
Capellero S, Erriquez J, Battistini C, et al. Ovarian cancer cells in ascites form aggregates that display a hybrid epithelial-mesenchymal phenotype and allows survival and proliferation of metastasizing cells[J]. Int J Mol Sci, 2022, 23(2): 833-833. DOI: 10.3390/ijms23020833.
|
| [9] |
Csorba R, Buderath P, Ingenwerth M, et al. Isolated abdominal wall metastasis 42 years after curative surgery for ovarian cancer: a case report[J]. Case Rep Womens Health, 2025, 45: e00696. DOI: 10.1016/j.crwh.2025.e00696.
|
| [10] |
Pavlakis G, Mountzios G, Terpos E, et al. Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature[J]. Int J Gynecol Cancer, 2006, 16 Suppl 1: 299-303. DOI: 10.1111/j.1525-1438.2006.00208.x.
|
| [11] |
Chen C, Yingyao O, Yan X, et al. Metastasis of ovarian cancer to nasal skin and skin on the trunk: a rare case report[J]. Front Oncol, 2023, 13: 1266820. DOI: 10.3389/fonc.2023.1266820.
|
| [12] |
朱莉, 秦丽, 王瑞雅, 等. 血清CA125、HE4、VEGF及ROMA指数对卵巢癌诊断及预测术后复发的价值[J]. 广东医学, 2021, 42(7): 796-801. DOI: 10.13820/j.cnki.gdyx.20204081.
|
| [13] |
Du K, Li Q, Huang J, et al. An increase of serum CA-125 to two times of nadir level strongly predicts the image-identified relapse of serous ovarian cancer[J]. Sci Rep, 2024, 14(1): 14986. DOI: 10.1038/s41598-024-65760-4.
|
| [14] |
Dai Z, Maihemuti M, Sun Y, et al. Resection and reconstruction of huge tumors in the chest wall[J]. J Cardiothorac Surg, 2022, 17(1): 116. DOI: 10.1186/s13019-022-01877-9.
|
| [15] |
Gonfiotti A, Salvicchi A, Voltolini L. Chest-wall tumors and surgical techniques: state-of-the-art and our institutional experience[J]. J Clin Med, 2022, 11(19): 5516. DOI: 10.3390/jcm11195516.
|
| [16] |
周学欣, 张汝, 鲍伟, 等. 复发性上皮性卵巢癌的药物治疗进展[J]. 中国计划生育和妇产科, 2021, 13(11): 6-10. DOI: 10.3969/j.issn.1674-4020.2021.11.02.
|
| [17] |
龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190. DOI: 10.3760/cma.j.cn371439-20231109-00030.
|
| [18] |
Huo X, Tian T, Zhang X, et al. Comparative effectiveness and safety of treatment regimens for recurrent advanced ovarian cancer: a systematic review and network meta-analysis[J]. World J Surg Oncol, 2025, 23(1): 134. DOI: 10.1186/s12957-025-03770-w.
|
| [19] |
Tanaka T, Takehara K, Usami T, et al. Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study[J]. Gynecol Oncol Rep, 2025: 101740. DOI: 10.1016/j.gore.2025.101740.
|
)
